Bromantane (also known by the trade name Ladasten) is an adamantane-derived drug developed and used in Russia, historically positioned as an “anti-asthenic” agent—aimed at pathological fatigue, low drive, and reduced capacity to function.

In online nootropics communities it is often discussed as a “clean stimulant”: energizing without the jitteriness and rebound associated with classical psychostimulants. The key scientific question is whether that reputation is supported by human neurocognitive evidence, and what neural mechanisms could plausibly explain it.

The short, evidence-based answer: bromantane has the best human data in fatigue/asthenia-related syndromes, with signals suggesting improvements in wellbeing, drive, sleep, and functional status. Evidence for direct cognitive enhancement in healthy people is much thinner, consisting mainly of small psychophysiology/EEG work and older trials published largely in Russian-language journals.

The Clinical Evidence

One of the largest published clinical datasets comes from a 28-center Russian study that analyzed outcomes in 728 patients with psychoautonomic syndrome and asthenic symptoms treated for 28 days with 50–100 mg/day bromantane (Voznesenskaia et al. 2010). Across repeated assessments (baseline; days 3, 7, 14, 28; and one month after stopping), the authors reported:

• Onset of anti-asthenic effect by day 3
• Responder rates of 76.0% on CGI-S and 90.8% on CGI-I (Clinical Global Impression–Severity & Clinical Global Impression–Improvement). There are a clinician’s single overall rating of how severe a patient’s illness is right now (typically on a 1–7 scale from normal to extremely ill).
• Reported persistence of benefit one month after discontinuation
• Broad improvements described across anxiety–depressive symptoms, autonomic complaints, sleep issues, and quality-of-life measures (Voznesenskaia et al. 2010).

This focus of this study was not cognitive enhancement per se; it is closer to the “fatigue, drive, and daily functioning” end of cognition. But these domains—motivation, sustained effort, sleep–wake regularity—often feel like cognition from the inside, because they strongly shape attention and productivity.

In terms of cognitive enhancement in healthy people, the most directly relevant human study indexed in PubMed is a small placebo comparison in 10 healthy volunteers using EEG and psychophysiological measures after a single oral dose (Viatleva et al. 2000). The authors reported a “favorable influence” on functional state relevant to operator performance, and an EEG pattern described as:

• increased middle-frequency alpha power
• decreased delta and beta1 band power

They interpret this as similar to profiles seen with “moderate psychostimulating, antiamnestic and antihypoxic” drugs (Viatleva et al. 2000). Though this result is intriguing it is also a reminder of the evidence gap: n=10 and older methods do not equal a modern, pre-registered cognitive-enhancement trial with robust statistics.

Mechanism of action (a calm stimulant)

Bromantane is often described as unusual because its stimulation is reported alongside anxiolytic features. Mechanistically, the best-supported elements point to dopaminergic modulation with additional effects on monoamines and neural signaling pathways.

Dopamine release and dopamine synthesis machinery

Animal neurochemistry studies suggest bromantane can increase dopamine release in the striatum and alter dopamine metabolism—shown using in vivo microdialysis in freely moving rats (Grekhova et al. 1995).

Beyond acute release, work in rats indicates bromantane can regulate tyrosine hydroxylase (TH)—the rate-limiting enzyme for dopamine synthesis—at the mRNA/protein level in dopaminergic regions (Mikhaylova et al. 2007). A plausible interpretation is that bromantane may produce a dual dopaminergic effect:

1. short-term: more dopamine available at synapses (release/metabolism changes)
2. longer-term: altered capacity for dopamine synthesis via TH regulation

That combination can, in theory, support sustained motivation/drive without the sharp peaks typical of strong dopamine releasers.

Effects beyond dopamine: serotonin and brain-state signatures

Rodent work also reports changes in serotonin (5-HT) and its metabolite 5-HIAA in cortex and subcortical regions after bromantane exposure (Kudrin et al. 1995).

Meanwhile, electrophysiological findings in animals indicate bromantane can modify bioelectrical activity across cortical and subcortical structures (Krapivin et al. 1998).
The human EEG study’s shift toward higher alpha power and reduced delta (Viatleva et al. 2000) is consistent with the idea that bromantane may nudge the brain toward a more alert-but-stable state rather than a high-beta “wired” profile.

Neuroplasticity Signalling

Some preclinical lines of work on Ladasten/bromantane discuss effects on intracellular signalling and neurotrophic factors (e.g., MAPK/ERK pathways, BDNF/NGF gene expression), though these are not the same as demonstrating cognitive enhancement in humans.

Bromantane as a nootropic

If a person’s “cognition” is impaired primarily by fatigue, low motivation, dysregulated sleep, and autonomic symptoms, then the clinical literature supports bromantane as a drug with meaningful effects in that space.

Most notably the large multicenter study reporting 76.0% (CGI-S) and 90.8% (CGI-I) responder rates and early improvement by day 3 with 50–100 mg/day (Voznesenskaia et al. 2010). These outcomes can translate into better concentration and productivity indirectly—because attention is often the first casualty of fatigue.

For healthy users hoping for reliably better memory, faster learning, or higher test scores, the publicly indexed human evidence is limited. The 10-person EEG/psychophysiology study suggests potential benefits on attention-like operator metrics (Viatleva et al. 2000), but it is far from the kind of dataset that would settle efficacy questions for the general population.

In the 728-patient clinical dataset, bromantane was described as well tolerated and benefits reportedly persisted after stopping (Voznesenskaia et al. 2010).
However, the broader international evidence base is not as deep as for widely used wakefulness agents (e.g., modafinil) or ADHD stimulants.

Bromantane’s neurological “signature,” as reflected in the literature, is best described as dopamine-centered arousal modulation with additional monoaminergic and signaling effects. Clinically, the strongest human evidence supports improvements in asthenic states—conditions where fatigue, low drive, and dysregulated sleep compress cognitive performance from the outside in.

References

Voznesenskaia TG, Fokina NM, Iakhno NN. 2010. Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten. Zh Nevrol Psikhiatr Im S S Korsakova. PMID: 21322821. “https://pubmed.ncbi.nlm.nih.gov/21322821/
“

Neznamov GG et al. 2009. Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo). PMID: 19491814. “https://pubmed.ncbi.nlm.nih.gov/19491814/
“

Viatleva OA et al. 2000. The neuro- and psychophysiological effects of bromantane. PMID: 10998997. “https://pubmed.ncbi.nlm.nih.gov/10998997/
“

Grekhova TV, Gainetdinov RR, Sotnikova TD, et al. 1995. The effect of bromantane… on release and metabolism of dopamine in the dorsal striatum of freely moving rats: a microdialysis study. PMID: 7795203. “https://pubmed.ncbi.nlm.nih.gov/7795203/
“

Kudrin VS et al. 1995. The effect of bromantane on the dopamine- and 5-hydroxytryptaminergic systems of rat brain. PMID: 7580761. “https://pubmed.ncbi.nlm.nih.gov/7580761/
“

Krapivin SV et al. 1998. Comparative analysis of the effects of adapromine, midantane, and bromantane on bioelectrical activity of the brain cortex and subcortical structures. “https://link.springer.com/article/10.1007/BF02496845
“

Mikhaylova M, Behnisch T, et al. 2007. The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats. PMID: 17854844. “https://pubmed.ncbi.nlm.nih.gov/17854844/
” (ScienceDirect landing page: “https://www.sciencedirect.com/science/article/abs/pii/S0028390807002109
“)

Vanhee C et al. 2025. The Occurrence of Illicit Smart Drugs or Nootropics in Europe and Australia and Their Associated Dangers: Results from a Market Surveillance Study… (PMC). “https://pmc.ncbi.nlm.nih.gov/articles/PMC12193813/
” (PubMed record: “https://pubmed.ncbi.nlm.nih.gov/40558871/
“)